David F Burgstahler
CIK 1374179 · President and CEO · last filed 2023-01-30
David F Burgstahler is a President and CEO who has filed 41 SEC Form 4 insider transactions across 11 companies since 2007. Across all open-market trades the lifetime net is −$123.2M, making them a net seller over the disclosed history. Current disclosed insider exposure totals $76.5M across reported positions. 26 SEC filings were submitted jointly with Thompson Dean.
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
$76.45M
11
41
-$123.20M
Filer Profile
100 ENTERPRISE DRIVE
ROCKAWAY, NJ 07866
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| RVL Pharmaceuticals plc (RVLP) Delisted | Director | 0 | $0.03 | $0 | $12.40M | 2 | 2023-01-30 |
| OABIW | Director | 15,871,242 | $0.37 | $5.83M | $0 | 2 | 2023-01-05 |
| RVL Pharmaceuticals plc (OSMT) Delisted | Director | 15,730,864 | $1.11 | $17.46M | $6.25M | 2 | 2020-11-23 |
| ORGO | Director | 29,840,171 | $1.49 | $44.46M | $116.01M | 1 | 2020-11-19 |
| WideOpenWest, Inc. (WOW) Delisted | Director | 27,145,193 | $5.20 | $141.16M | $0 | 3 | 2019-05-13 |
| LNTH | Director | 260,501 | $100.25 | $26.12M | -$154.91M | 9 | 2017-09-11 |
| Organogenesis Holdings Inc. (AHPAW) Delisted | President and CEO | — | $0.69 | — | $0 | 1 | 2017-07-07 |
| INCR | Director | 8,482 | $5.16 | $43.8K | $43.2K | 4 | 2017-05-24 |
| ANGIODYNAMICS INC (ANGO.V) Delisted | Director | 1,470,401 | — | — | -$103.29M | 10 | 2017-04-14 |
| Organogenesis Holdings Inc. (AHPAU) Delisted | President and CEO | — | $6.16 | — | $0 | 1 | 2016-11-29 |
| Warner Chilcott plc (WCRX) Delisted | Director | 20,000 | — | — | $304.2K | 4 | 2009-08-07 |
Recent Filings
41 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2023-09-25 | — | Notice (144) | −670,694 | -$60.4K | EDGAR |
| 2023-08-24 | — | Notice (144) | −767,515 | -$105.8K | EDGAR |
| 2023-01-30 | RVL Pharmaceuticals plc (RVLP) Delisted | Other (J) | −1,032,995 | $0 | EDGAR |
| 2023-01-05 | OABIW | Grant (A) | +373,156 | $0 | EDGAR |
| 2022-12-05 | OABIW | Grant (A) | — | $0 | EDGAR |
| 2022-08-09 | RVL Pharmaceuticals plc (RVLP) Delisted | Buy (P) | +8,000,000 | $12.40M | EDGAR |
| 2020-11-23 | RVL Pharmaceuticals plc (OSMT) Delisted | Other (J) | −4,936,926 | $0 | EDGAR |
| 2020-11-19 | ORGO | Buy (P) | +35,233,296 | $116.01M | EDGAR |
| 2020-01-15 | RVL Pharmaceuticals plc (OSMT) Delisted | Buy (P) | +1,250,000 | $6.25M | EDGAR |
| 2019-05-13 | WideOpenWest, Inc. (WOW) Delisted | Grant (A) | +218,512 | $0 | EDGAR |
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.